I should speak about having updates now often! J
Post# of 9122
(Total Views: 476)
Posted On: 03/10/2021 12:19:27 AM
I should speak about having updates now often! Just got this email update from the Company:
NanoLogix Provides the following as an update on the Development and Use of the recently Patented COVID-19 Detection Technology.
The Company is pleased to announce the achievment of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
What do these mean?
The RVA, unlike PCR technology, detects the whole virus and will not react to the presence of dead or nonpathogenic viral particles. This essentially eliminates false positives. (More routine testing such as PCR is plagued by false positives, due to the inability of PCR to distinguish between fragments of inactive virus and intact virus.)
The low threshhold for detection (meaning the RVA is more sensitive than other common tests), reduces the potential for false negative readings.
The RVA, as a detector of whole virions, should be able to detect pathogenic mutations, or variants, for the targeted virus. This means that as the virus continues to mutate and evolve, the RVA does not have to be modified in order to continue to maintain its accuracy.
The RVA development research is currently focused upon adaptation to a cartridge format that will provide ease of use and affordability.
The RVA is the only technology we know that tests for the whole virus.
The RVA is the only technology we know that is capable of determining if an individual is contagious.
NanoLogix Provides the following as an update on the Development and Use of the recently Patented COVID-19 Detection Technology.
The Company is pleased to announce the achievment of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
What do these mean?
The RVA, unlike PCR technology, detects the whole virus and will not react to the presence of dead or nonpathogenic viral particles. This essentially eliminates false positives. (More routine testing such as PCR is plagued by false positives, due to the inability of PCR to distinguish between fragments of inactive virus and intact virus.)
The low threshhold for detection (meaning the RVA is more sensitive than other common tests), reduces the potential for false negative readings.
The RVA, as a detector of whole virions, should be able to detect pathogenic mutations, or variants, for the targeted virus. This means that as the virus continues to mutate and evolve, the RVA does not have to be modified in order to continue to maintain its accuracy.
The RVA development research is currently focused upon adaptation to a cartridge format that will provide ease of use and affordability.
The RVA is the only technology we know that tests for the whole virus.
The RVA is the only technology we know that is capable of determining if an individual is contagious.
(5)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼